Upon joining the study, you will be randomly assigned to one of two groups: Arm A or Arm B. This process is called randomization and ensures that each participant has an equal chance of receiving either treatment.

If assigned to Arm A, you will receive a combination of ociperlimab and tislelizumab. Both medications are administered as an infusion, which means they are given directly into your bloodstream through a vein.

The specific dosage and frequency of these infusions will be determined by the study protocol and your healthcare provider.

If assigned to Arm B, you will receive pembrolizumab followed by a placebo. Pembrolizumab is also administered as an infusion.

The placebo is a substance with no active medication, used to compare the effects of pembrolizumab. The dosage and frequency will be specified by the study protocol.

Throughout the study, regular monitoring and assessments will be conducted to evaluate your health and the effects of the treatment.

These assessments may include physical exams, blood tests, imaging studies, and questionnaires about your quality of life.

The treatment phase will continue until the study’s end date or until it is determined that you should stop treatment for any reason, such as side effects or disease progression.

Your healthcare provider will discuss the next steps with you at the end of the treatment phase.

After completing the treatment phase, follow-up visits will be scheduled to monitor your health and gather additional information about the long-term effects of the treatment.

These visits are an important part of the study to ensure your well-being and to collect data for the study’s objectives.